Search trials – HealthDB

AI · diabetes

Намерени 206 изпитвания за "diabetes" Стр. 10 от 11

Active (not recruiting)

Effects of Chestnuts on Postprandial Glycaemic Response

Postprandial Glycemia Insulin Resistance

Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols. Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.

Начало: 06.06.2025 Край: 30.04.2026 Възраст: 18–65 г. Other

Australia Monash University NCT06960967

Active (not recruiting) Phase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity Overweight

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.

Начало: 15.05.2025 Край: 01.08.2027 Възраст: от 18 г.

Argentina, China, Czechia +4 Eli Lilly and Company NCT06972459

Active (not recruiting) Phase 2

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Obesity Overweight or Obesity

This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.

Начало: 01.04.2025 Край: 01.10.2026 Възраст: 18–70 г.

United States Metsera, a wholly owned subsidiary of Pfizer NCT06973720

Active (not recruiting) Phase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Obesity

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Начало: 12.03.2025 Край: 16.04.2027 Възраст: 18–99 г. Treatment

Argentina, Australia, Belgium +13 Amgen NCT06858839

Active (not recruiting) Phase 3

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

HIV Infections Weight Gain

People with HIV are at a higher risk of cardiovascular diseases (CVD) due to the effects of the virus and its treatment. Integrase strand transfer inhibitors (INSTIs), a common HIV treatment, are associated with increased CVD risk and metabolic issues, such as weight gain and high blood pressure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, however, have been working well in reducing CVD events and hospitalizations due to heart failure, irrespective of diabetes presence. They also help in reducing weight and blood pressure. Pitavastatin has shown to work in lowering CVD events in people with HIV, but its availability is limited. This benefit is thought to be common to all statins, but this has not yet been confirmed. This study will examine the impact of dapagliflozin vs. placebo on metabolic parameters in people with HIV with high metabolic risk who are on INSTI-based ART.

Начало: 16.12.2024 Край: 01.12.2026 Възраст: 40–75 г. Treatment

Argentina, Australia, India +6 Kirby Institute NCT06317051

Active (not recruiting)

Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

Heart Diseases Cardiovascular Diseases Heart Failure

Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). Dapagliflozin was recently granted approval for heart failure by the European Commission, regardless of ejection fraction and whether the patient has diabetes. Real-world observational data are necessary to describe dapagliflozin use in real-world settings in order to assess treatment patterns, HF symptoms and their impact on physical limitation, HRQoL and work productivity, as well as health care utilization of patients treated with dapagliflozin in this setting under local treatment standard conditions in Germany.

Начало: 25.04.2024 Край: 31.12.2026 Възраст: 18–130 г.

Germany AstraZeneca NCT06336330

Active (not recruiting)

BCG Revaccination Study in Diabetic and Non-Diabetic Adults

Tuberculosis

The purpose of this study is to: 1. explore whether investigators can make BCG more effective by giving it in a different way. For this, aerosol inhaled BCG will be compared against the conventional BCG injection. 2. explore if there are differences in response to re-vaccination in healthy volunteers with and without Type 2 Diabetes. It will involve 36 previously BCG-vaccinated participants. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity.

Начало: 03.04.2024 Край: 31.08.2028 Възраст: 18–65 г.

United Kingdom University of Oxford NCT06246851

Active (not recruiting)

Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)

Type 1 Diabetes Celiac Disease

The purpose of this study is to identify people with T1D or celiac disease (CD) early in the course of their disease and to improve the methods of screening for these diseases.

Начало: 11.03.2024 Край: 01.06.2026 Възраст: от 2 г.

United States AdventHealth Translational Research Institute NCT06908057

Active (not recruiting)

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment Neovascular Age-related Macular Degeneration (nAMD) Diabetic Macula Edema (DME)

This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors. In this study, data from adults with visual impairment due to neovascular age-related macular degeneration (nAMD) or diabetic macula edema (DME) will be collected and studied. Visual impairment is any degree of vision loss that affects a person's ability to perform daily activities. nAMD is an eye disorder that causes vision loss due to the growth of abnormal blood vessels that leak blood or retinal fluid into the macula (the central part of the retina). nAMD is a leading cause of vision loss for people aged 50 and older. DME is a diabetes-related eye disorder. In DME, the macula swells up due to fluid leakage from damaged blood vessels, resulting in vision problems. Aflibercept 8 mg is a drug that is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye. Aflibercept 8 mg has been submitted for approval for the treatment of visual impairment due to nAMD and DME based on the results from 2 studies called PHOTON and PULSAR. This study will begin once approval is obtained. Currently, no real-world data are available for aflibercept 8 mg. The main purpose of this study is to collect more information about how well aflibercept 8 mg injection works in people with nAMD and DME. This study will include participants who have not received any prior treatment for nAMD or DME and participants who have. The main information that researchers will collect: the change in vision test scores called the best corrected visual acuity (BCVA) after 12 months of treatment. Data will be collected from February 2024 to September 2027 and will cover a period of up to 24 months per participant. The data will be collected using medical records and by interviewing the patients during regular visits that take place in routine practice. Researchers will observe participants from the first injection of aflibercept 8 mg until the end of the observation. In this study, only available data from regular visits will be collected. No visits or tests are required as part of this study.

Начало: 15.02.2024 Край: 31.01.2028 Възраст: от 18 г.

Australia, Canada, Denmark +13 Bayer NCT06075147

Active (not recruiting) Phase 2

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Type 1 Diabetes Mellitus

The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.

Начало: 30.10.2023 Край: 31.03.2029 Възраст: 8–45 г. Treatment

Australia, United States National Institute of Diabetes and Digestive and Kidney NCT03929601

Active (not recruiting) Phase 3

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

Obesity

This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults. The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).

Начало: 07.07.2023 Край: 07.12.2026 Възраст: 6–18 г.

Austria, Belgium, Denmark +7 Novo Nordisk A/S NCT05726227

Active (not recruiting) Phase 3

Preventing Cognitive Decline with Metformin

Cognitive Decline

A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.

Начало: 15.07.2022 Край: 01.12.2027 Възраст: 60–80 г. Treatment

Australia Garvan Institute of Medical Research NCT04511416

Active (not recruiting)

Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-Induced Peripheral Neuropathy Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual approach for treating CIPN is treatment with drugs that help reduce symptoms of other types of neuropathy (for example, from diabetes). However, these drugs do not treat all symptoms of CIPN. Exercise may help to reduce CIPN symptoms.

Начало: 25.02.2022 Край: 30.06.2026 Възраст: от 18 г.

United States University of Rochester NCORP Research Base NCT04888988

Active (not recruiting) Phase 3

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.

Начало: 01.04.2021 Край: 25.04.2029 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +33 Novo Nordisk A/S NCT04822181

Active (not recruiting)

Mechanisms of Prediabetic States in Sleep Apnea

Sleep Apnea Pre-diabetes

The purpose of this study is to better understand how sleep apnea contributes to the development of diabetes.

Начало: 26.11.2019 Край: 15.07.2026 Възраст: 20–65 г.

United States University of Chicago NCT04234217

Active (not recruiting)

Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation

Obstructive Sleep Apnea Hodgkin Lymphoma

While thoracic radiation therapy (TRT) has been a primary component in successful treatment of Hodgkin lymphoma, exposure to this treatment has been associated with significant cardiovascular, cerebrovascular, and pulmonary morbidity in long-term survivors. Survivors of Hodgkin lymphoma (HL) are also at risk for fatigue and excessive daytime sleepiness. Insufficient sleep is recognized as an important public health concern, and is associated with cardiovascular disease, diabetes, obesity, neurocognitive problems, and reduced quality of life and productivity. Survivors of HL, who are already at risk for cardiac and neurologic morbidity due to their treatment exposures, could face catastrophic cardiovascular and cerebrovascular events with the added risk associated with obstructive sleep apnea (OSA). The investigators propose to examine indices of sleep quality using polysomnography, and associated neurocognitive performance, brain MRI, and structure and strength of neck muscles in 220 long-term adult survivors of Hodgkin lymphoma treated with thoracic radiation. OBJECTIVES: 1. To estimate the prevalence of OSA in adult survivors of HL treated with thoracic radiation, and compare the frequency to community controls matched on age, gender, race and body mass index. 2. To identify specific therapeutic factors associated with OSA in adult survivors of HL treated with thoracic radiation. 3. To identify biomarkers of OSA in adult survivors of HL treated with thoracic radiation. 4. To examine associations between OSA and cardiac morbidity and brain integrity in the adult survivors of HL treated with thoracic radiation.

Начало: 23.01.2018 Край: 10.07.2028 Възраст: от 18 г.

United States St. Jude Children's Research Hospital NCT03361020

Active (not recruiting)

Comparative Effectiveness of Empagliflozin in the US

Diabetes Mellitus, Type 2

Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014. In contrast with several previous cardiovascular outcomes trials, which failed to demonstrate an association with a higher or a lower risk of cardiovascular outcomes associated with members of other recently marketed antidiabetic classes, the EMPA-REG OUTCOME trial has shown that patients at high cardiovascular risk randomized to empagliflozin vs. placebo, were associated with a reduced risk of hospitalization for heart failure, cardiovascular mortality, and all-cause mortality. However, these and other findings arising from an extensive clinical trial program aimed at evaluating the efficacy and safety profile for empagliflozin have yet to be demonstrated in a non-trial environment. This study aims to investigate the transferability of the effects demonstrated in dedicated randomized clinical studies to a broader population under real world conditions.

Начало: 16.10.2017 Край: 31.05.2026 Възраст: от 18 г.

United States Boehringer Ingelheim NCT03363464

Active (not recruiting) Phase 2

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

Diabetes Lipodystrophy Hyperlipidemia

Background: \- Partial lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes. Researchers have found that the drug metreleptin improves health in people with this disease. Objective: \- To test the safety and effectiveness of metreleptin. Eligibility: * People age 6 months and older with partial lipodystrophy who * have received metreleptin through NIH studies and shown improvement AND * cannot get metreleptin other ways. Design: * Participants will come to NIH approximately every 6 months during year one, then every 1 2 years. Financial assistance may be available for travel within the U.S. * At visits, participants will get a supply of metreleptin to take home for daily injections, or it can be shipped to them inside the U.S. They will have: * plastic catheter placed in an arm vein. * blood tests, urine collection, and physical exam. * oral glucose tolerance test, drinking a sweet liquid. * ultrasound of the heart, liver, uterus, and ovaries. A gel and a probe are placed on the skin and pictures are taken of the organs. * echocardiogram, which takes pictures of the heart with sound waves. * Resting Metabolic Rate taken. A plastic hood is worn over the head while the oxygen they breathe is measured. * Participants will have up to 3 DEXA scan x-rays per year. * Participants may have: * annual bone x-rays. * liver biopsies every few years. A needle will be inserted into the liver to obtain a small piece. Participants will sign a separate consent for this. * Participants must be seen regularly by their local doctors and have blood tests at least every 3-6 months at home.

Начало: 14.10.2014 Край: 31.07.2027 Възраст: 6–98 г.

United States National Institute of Diabetes and Digestive and Kidney NCT02262806

Active (not recruiting)

Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?

Prediabetes Healthy (Controls)

Brief Summary The goal of this clinical trial is to learn whether older adults with prediabetes, but no diagnosed cognitive impairment, show early changes in brain energy use and thinking speed compared to older adults with normal blood sugar levels. The study will also test whether a single dose of an exogenous ketone supplement can improve brain energy use and cognitive processing speed. The main questions it aims to answer are: Do older adults with prediabetes have lower brain glucose uptake and slower cognitive processing speed compared to those with normal glucose levels? Does a single dose of an exogenous ketone monoester supplement improve cognitive processing speed and brain glucose uptake? Researchers will compare older adults with prediabetes to older adults with normal glucose levels to determine whether differences exist in brain glucose metabolism and cognitive performance. In a subset of participants, researchers will also compare brain and cognitive outcomes before and after consuming a ketone monoester supplement (DeltaG, Oxford, England). Participants will: Complete metabolic testing to determine glucose status Undergo brain imaging using fluorodeoxyglucose positron emission tomography combined with magnetic resonance imaging (18FDG-PET/MRI) while performing a cognitive processing speed task Consume a single dose of a commercially available ketone monoester supplement during one study visit Complete cognitive testing during imaging to measure processing speed and brain activity The results of this study will help determine whether early metabolic dysfunction is linked to reduced brain energy use and whether ketones can temporarily support brain function in individuals at risk for dementia.

Начало: 20.05.2025 Край: 31.05.2026 Възраст: 60–75 г.

United States University of Alabama at Birmingham NCT07546409

By invitation only

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Diabetes Cardiovascular Disease

Background: \- African Americans have one of the highest rates of type 2 diabetes in the United States, and often have other medical problems related to obesity and cardiovascular disease. These conditions have various risk factors, including high blood sugar levels, high cholesterol levels, and insulin resistance. However, these risk factors have not been studied very closely in individuals with African ancestry, including Afro-Caribbean and sub-Saharan Africa migrant populations. Researchers are interested in conducting a genetic study on obesity, adult-onset diabetes, heart disease, and other common health conditions in individuals with African ancestry. Objectives: \- To collect genetic and non-genetic information from individuals with African ancestry to study common health conditions related to obesity, adult-onset diabetes, and heart disease. Eligibility: \- Individuals at least 18 years of age who self-identify as African American, Afro-Caribbean, or migrants from sub Saharan Africa. Design: * Participants will undergo a physical examination and will provide a blood sample for study. * Participants will also answer questions about personal and family medical history and current lifestyle behaviors. * No treatment will be provided as part of this protocol.

Начало: 06.05.2011 Възраст: 18–120 г.

United States National Human Genome Research Institute (NHGRI) NCT01316783

1 … 8 9 10 11